There are 3,961 papers on HbA1c in aging research: 915 trials and 2,164 observational studies in people, 42 in animals, 2 in cells, 662 reviews.
3,961 papers study it511 more mention it1,934 findings
427 new papers in 30 daysSee all 4,472 papers on HbA1c
At a glance
A human cohort links HbA1c with mortality in a U-shaped pattern in the general population, while an observational preprint links higher HbA1c with greater frailty in adults with diabetes. Human trials report HbA1c reductions with semaglutide and resistance training; a dapagliflozin trial shows no clear effect.
1,934 findings in 1,603 papers from 1978 to 2026, 436 of them since April 2026
“Higher baseline HbA1c was associated with lower remission rates (HR 0.23, 95% CI 0.18-0.29, p < 0.001)”
- Human trial915
- Humans2,164
- Animals42
- Cells2
- In silico50
Interventions
218Tirzepatide
downin humans35−1.5% to −0.6%
35 studies
Tirzepatide
downin humans35−1.5% to −0.6%
Tirzepatide decreases HbA1c in humans (unadjusted indirect comparison with semaglutide) (-0.10% vs semaglutide [-0.15, -0.05]).
“HbA1c(-0.08% [-0.13,-0.03], -0.10% [-0.15, -0.05])”
Human trialunadjusted indirect comparison with semaglutide15 mg/week
International journal of obesity (2005)
Tirzepatide decreases HbA1c in adults with early uncontrolled T2D.
“tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y”
Human trialin adults with early uncontrolled T2D2 y
Annals of internal medicine
Tirzepatide decreases HbA1c in a patient with severe hypertriglyceridemia and type 2 diabetes (to 5.5% from 7.0%).
“HbA1c improved to 5.5%”
Human trialin a patient with severe hypertriglyceridemia and type 2 diabetesfemalesn = 1
Cardiovascular diabetology. Endocrinology reports
Tirzepatide decreases HbA1c in humans (compared with dulaglutide) (-2.18% (TZP) vs -1.28% (dula) at six months).
“At six months HbA1c was reduced more with TZP than on dula (-2.18%, -1.28%, p<0.001)”
Human trialcompared with dulaglutideup to 15 mg/weeksix monthsn = 449
ADA Scientific Sessions 2026 abstract
Tirzepatide decreases HbA1c in humans (switch from dulaglutide, across prespecified baseline subgroups).
“Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.”
Human trialswitch from dulaglutide, across prespecified baseline subgroupsweek 40
BMJ open diabetes research & care
Tirzepatide decreases HbA1c in humans (-0.77% (95% CI −0.98 to −0.56)).
“At week 40, the estimated treatment difference of tirzepatide compared with dulaglutide was −0.77% (95% CI −0.98 to −0.56, p<0.001) for HbA1c and −6.9 kg (95% CI−8.3 to −5.5, p<0.001) for body weight.”
Human trial40-week treatment periodn = 282
BMJ open diabetes research & care
Tirzepatide decreases HbA1c in humans (tirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses) (MD 0.33%; 95% CI 0.20, 0.46).
“tirzepatide was also more effective than semaglutide in reducing HbA1c (MD 0.33%; 95% CI: 0.20, 0.46)”
Human trialtirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses15 mg versus 2.4 mg
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Journal of diabetes
Tirzepatide is linked with lower HbA1c in humans (-1.5%).
“HbA1c levels and BMI decreased over 24 weeks after initiation of low-dose tirzepatide (HbA1c, -1.5%; BMI, -1.5 kg/m 2 ; both p < 0.001).”
Humansaverage 4.5 ± 1.0 mg/week24 weeksn = 88
Endocrine journal
Tirzepatide is linked with lower HbA1c in humans (combined with a standardized low-carbohydrate diet and tailored physical activity) (5.5 ± 0.4% to 5.2 ± 0.1%).
“Metabolic parameters were also improved, including HbA1c (from 5.5 ± 0.4% to 5.2 ± 0.1%, p = 0.007)”
Humanscombined with a standardized low-carbohydrate diet and tailored physical activityinitiated at 2.5 mg once weekly, increased to 5 mg; mean 5.32 mg24 weeksn = 122
Journal of diabetes and its complications
Tirzepatide is linked with lower HbA1c in humans (decreased by 16.0%).
“Fasting glucose, HbA1c, triglycerides, and alanine aminotransferase decreased by 19.5%, 16.0%, 8.5%, and 10.6%, respectively”
Humans12 months
Journal of the Endocrine Society
All 36Fewer
Semaglutide
downin humans28no changein humans1downin rats1−1.1% to −0.5%
30 studies
Semaglutide
downin humans28no changein humans1downin rats1−1.1% to −0.5%
Semaglutide decreases HbA1c in humans (A1c 8.0% to 6.6%).
“improved diabetes control (A1c 8.0% to 6.6%)”
Human trialFamilial hypobetalipoproteinemia and type 2 diabetes mellitus; concurrent fat-soluble vitamin supplementation and alendronate1 mg weekly18 monthsmalesn = 1
AHA Scientific Sessions 2026 abstract
Semaglutide decreases HbA1c in humans (-21.1 mmol/mol).
“significant reductions in HbA1c (-21.1 mmol/mol, P < .0001)”
Human trial≤2.0 mg weekly6 months
European heart journal
Semaglutide decreases HbA1c in humans (−21.1 mmol/mol).
“After 6 months of semaglutide, significant reductions in HbA1c (−21.1 mmol/mol, P <.0001), weight (−6.7 kg, P <.001), BMI (−2.5 kg/m, P <.001), and hsCRP (−1.0 mg/L, P =.005) were observed.”
Human trial24 weeksn = 16
European heart journal
Semaglutide decreases HbA1c in humans (− 0.64%-points (95% CI − 0.71, − 0.56)).
“Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was − 0.64%-points (− 0.71, − 0.56) (p < 0.0001) for the overall combined semaglutide–SGLT2i group.”
Human trial6 monthsn = 1,855
Diabetes therapy : research, treatment and education of diabetes and related disorders
Semaglutide decreases HbA1c in humans.
“HbA1c levels were reduced through week 24 from baseline in the test vs. reference group.”
Human trial24 weeksn = 217
Metabolism open
Semaglutide decreases HbA1c in humans (Added to standard treatment for inadequately controlled type 2 diabetes mellitus) (HbA1c decreased from 8.6±0.7% to 7±1%; difference: -1.6 percentage points).
“At 24 weeks, a reduction in glycosylated hemoglobin (HbA1c: 8.6±0.7% to 7±1%, difference: -1.6%)”
Human trialAdded to standard treatment for inadequately controlled type 2 diabetes mellitus0.5 or 1 mg weekly24 weeks79.8% womensn = 104
Revista medica de Chile
Semaglutide decreases HbA1c in humans (−0.9 percentage points).
“For the primary endpoint, a reduction in HbA1c from 7.9% (63 mmol/mol) to 6.9% (52 mmol/mol) was observed from BL to EOS, with an estimated mean change of −0.9 (95% CI: −1.2; −0.6) percentage points (p < 0.0001) or −9.9 (95% CI: −13.1; −6.6) mmol/mol (Figure 1, Supplementary table S5).”
Human trial34-44 weeksn = 97
Real-world use of oral semaglutide in adults with type 2 diabetes
Danish medical journal
Semaglutide decreases HbA1c in humans (persistent on dose to week 52, compared with 14 mg) (-2.1% vs -1.6% change from baseline).
“Individuals persistent on 25mg OS experienced a greater HbA1c reduction of -2.1% (baseline HbA1c 9.0%) compared to -1.6% (baseline HbA1c 8.9%) for those on 14mg.”
Human trialpersistent on dose to week 52, compared with 14 mg25 mg52 weeksn = 272
ADA Scientific Sessions 2026 abstract
Semaglutide decreases HbA1c in humans (adjunct to standard-of-care insulin vs SOC, Period 1 (weeks 1 to 26)) (-0.45% HbA1c vs SOC).
“In Period 1, HbA1c was reduced by 0.45% (95% CI -0.78, -0.127; p=0.0072)”
Human trialadjunct to standard-of-care insulin vs SOC, Period 1 (weeks 1 to 26)weekly injectionuptitrated to 1.0 mg weekly26 weeksn = 78
ADA Scientific Sessions 2026 abstract
Semaglutide decreases HbA1c in humans across baseline glycemia subgroups (nondiabetes, prediabetes, type 2 diabetes).
“HbA1c, BP, triglycerides, non-HDL, and hsCRP improved”
Human trialacross baseline glycemia subgroups (nondiabetes, prediabetes, type 2 diabetes)2.4 mgup to week 72n = 800
ADA Scientific Sessions 2026 abstract
All 33Fewer
GLP-1 receptor agonists
downin humans25no changein humans1upin humans1downin reviews1−0.6% to −0.3%
28 studies
GLP-1 receptor agonists
downin humans25no changein humans1upin humans1downin reviews1−0.6% to −0.3%
GLP-1 receptor agonists decrease HbA1c in humans (add-on to background glucose-lowering therapy) (MD -0.48% (95% CI -0.83 to -0.14)).
“low certainty indicated an HbA1c reduction (MD, - 0.48%; 95% CI, - 0.83 to - 0.14)”
Human trialadd-on to background glucose-lowering therapy
Frontiers in endocrinology
GLP-1 receptor agonists decrease HbA1c in diabetic patients with inflammatory bowel disease (7.11% (95% CI 6.62 to 7.59) to 6.76% (95% CI 6.35 to 7.16)).
“HbA1c, in diabetics, from 7.11% (95% CI: 6.62 to 7.59) to 6.76% (95% CI: 6.35 to 7.16)”
Human trialin diabetic patients with inflammatory bowel disease
Digestive diseases (Basel, Switzerland)
GLP-1 receptor agonists decrease HbA1c in kidney-transplanted people with post-transplant diabetes mellitus (−0.6% at 6 months (95% CI −0.8 to −0.4); −0.7% at 12 and 18 months).
“HbA1c significantly decreased by −0.6% at 6 months (95% CI −0.8 to −0.4)”
Human trialin kidney-transplanted people with post-transplant diabetes mellitus6 monthsn = 42
ADA Scientific Sessions 2026 abstract
GLP-1 receptor agonists decrease HbA1c in type 2 diabetes, versus placebo (MD -1.4% [-1.6%, -1.2%] for tirzepatide 15 mg).
“All once-weekly GLP-1RAs outperformed placebo in reducing HbA1c”
Human trialin type 2 diabetes, versus placebo
Diabetes research and clinical practice
GLP-1 receptor agonists are linked with lower HbA1c in humans (versus SGLT2 inhibitor initiators) (-0.261%).
“HbA1c decreased more with GLP-1RA (-0.261%; P = .032)”
Humansversus SGLT2 inhibitor initiators12 months
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
GLP-1 receptor agonists are linked with lower HbA1c in humans (switching among discontinuers of oral semaglutide) (Δ = -0.98%).
“switching to another GLP1 receptor agonist was the most common strategy (36.2%) and resulted in a further HbA1c reduction (Δ = -0.98%; p = 0.005)”
Humansswitching among discontinuers of oral semaglutiden = 232
Diabetes, obesity & metabolism
GLP-1 receptor agonists are linked with lower HbA1c in humans (-0.71% HbA1c reduction).
“GLP-1 RA users achieved a mean adjusted weight loss of -5.73% (p = 0.001) and an HbA1c reduction of -0.71% (p = 0.018)”
Humans12 monthsn = 610
Safety and Efficacy of GLP-1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes
Annals of clinical and translational neurology
GLP-1 receptor agonists are linked with lower HbA1c in humans (alone or as dual GIP/GLP-1RA therapy, in people with obesity and type 1 diabetes) (-0.48% (95% CI -0.74 to -0.22)).
“HbA1c (-0.48%; 95% CI: -0.74, -0.22; p < 0.001)”
Humansalone or as dual GIP/GLP-1RA therapy, in people with obesity and type 1 diabetes12 monthsn = 70
Diabetes/metabolism research and reviews
GLP-1 receptor agonists are linked with lower HbA1c in good responders with type 2 diabetes (-2.9 percentage points).
“HbA1c levels fell from 9.2% to 6.3% in good responders and 8.4% to 8.1% in poor responders, resulting in an absolute HbA1c reduction of 2.9% and 0.3%, respectively.”
Humansin good responders with type 2 diabetesafter 3 monthsn = 3,194
medRxivPreprint
GLP-1 receptor agonists were not clearly linked with HbA1c in Wolfram syndrome participants also on insulin.
“No statistically significant changes in HbA1c or body mass index were observed at one or two years.”
Humansin Wolfram syndrome participants also on insulinone or two years
Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients
Frontiers in endocrinology
All 28Fewer
SGLT2 inhibitors
downin humans11no changein humans4−0.4%
15 studies
SGLT2 inhibitors
downin humans11no changein humans4−0.4%
SGLT2 inhibitors decrease HbA1c in humans (type 2 diabetes; single-arm study) (−0.90 percentage points (9.8 mmol/mol); 95% CI −1.10 to −0.69; P<0.001).
“Over 12 weeks, HbA1c decreased by 0.90 percentage points (9.8 mmol/mol; 95% CI, −1.10 to −0.69)”
Human trialtype 2 diabetes; single-arm study12 weeksn = 44
Frontiers in endocrinology
SGLT2 inhibitors showed no clear effect on HbA1c in humans (add-on to background glucose-lowering therapy) (MD -0.09% (95% CI -0.27 to 0.08)).
“little or no clinically important further benefit observed for HbA1c”
Human trialadd-on to background glucose-lowering therapy
Frontiers in endocrinology
SGLT2 inhibitors decrease HbA1c in humans (as add-on to insulin therapy) (MD -0.29%).
“Reductions were observed in HbA1c (MD -0.29%; p = 0.07)”
Human trialas add-on to insulin therapy
Primary care diabetes
SGLT2 inhibitors are linked with lower HbA1c in humans (type 2 diabetes without comorbidities).
“Significant reductions were observed in glucose and HbA1c levels.”
Humanstype 2 diabetes without comorbidities6 monthsn = 206
Intercontinental Journal of Internal Medicine
SGLT2 inhibitors were not clearly linked with HbA1c in humans (Kidney transplant recipients with post-transplantation diabetes mellitus) (52 vs. 49 mmol/mol; p = .11).
“Our study could not demonstrate improved metabolic parameters in PTDM patients treated with SGLT2-inhibitors at 5 years post transplantation.”
HumansKidney transplant recipients with post-transplantation diabetes mellitus5 years after transplantationn = 232
Transplantation proceedings
SGLT2 inhibitors are linked with lower HbA1c in humans (real-life retrospective cohort; short-term follow-up) (median 7.8% to 7.3% short-term).
“HbA1c from 7.8 [7.1-8.8] to 7.3 [6.7-7.7] and 7.3% [6.9-8] (p < 0.01 and p = 0.05, respectively)”
Humansreal-life retrospective cohort; short-term follow-up6-18 months
Diabetes, obesity & metabolism
SGLT2 inhibitors were not clearly linked with HbA1c in humans after multivariable adjustment.
“Descriptive between-group differences in HbA1c were observed at 6 and 12 months, but were not confirmed after multivariable adjustment.”
Humansafter multivariable adjustment6 and 12 months
Frontiers in transplantation
SGLT2 inhibitors are linked with lower HbA1c in humans (patients with baseline HbA1c ≥8%) (9.6% ± 1.3% to 7.6% ± 0.7%).
“HbA1c remained stable overall but decreased significantly in patients with baseline HbA1c ≥ 8% (9.6% ± 1.3% to 7.6% ± 0.7%; p = 0.001)”
Humanspatients with baseline HbA1c ≥8%
Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study
Diabetes, obesity & metabolism
SGLT2 inhibitors are linked with lower HbA1c in humans (all initiators with available follow-up data) (-0.62% (SD 1.53, n=105); -0.79% in diabetes/metabolic subgroup (SD 1.75; n=76)).
“HbA1c decreased by 0.62% among all initiators with available follow up data (SD 1.53, n=105), and by 0.79% in the diabetes/metabolic subgroup (SD 1.75; n=76).”
Humansall initiators with available follow-up datan = 105
Real-World Safety and Clinical Outcomes of SGLT2 Inhibitors in 195 Pediatric Patients
ADA Scientific Sessions 2026 abstract
SGLT2 inhibitors are linked with lower HbA1c in humans (Type 2 Diabetes) (control: -0.093% vs. treatment: -0.76%).
“HbA1c (control: -0.093% vs. treatment: -0.76%; p ≤ 0.001)”
HumansType 2 Diabetes> 6 monthsn = 200
Impact of SGLT2 Inhibitors on Multiple Cardiometabolic Risk Factors: A Retrospective Cohort Study
Journal of clinical medicine
All 15Fewer
Orforglipron
downin humans11upin humans1
12 studies
Orforglipron
downin humans11upin humans1
Orforglipron decreases HbA1c in humans (Type 2 diabetes inadequately controlled with metformin; compared with dapagliflozin).
“In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than dapagliflozin at 40 wk”
Human trialType 2 diabetes inadequately controlled with metformin; compared with dapagliflozin40 weeks
Annals of internal medicine
Orforglipron decreases HbA1c in humans (head-to-head comparison, 36 mg vs 12 mg maintenance dose).
“greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001), HbA1c”
Human trialhead-to-head comparison, 36 mg vs 12 mg maintenance dose36 mg versus 12 mgn = 3,459
BMC endocrine disorders
Orforglipron decreases HbA1c in humans (MD: 0.08% points; CI: 0.05 to 0.10).
“The 36-mg dose of Orforglipron was associated with a significantly greater reduction in HbA1c (in percentage points) compared with the 12-mg dose (MD: 0.08% points; CI: 0.05 to 0.10; p < 0.00001; I2 = 39%).”
Human trial26 to 72 weeksn = 3,459
BMC endocrine disorders
Orforglipron decreases HbA1c in humans.
“Once-daily orforglipron treatment in older adults ≥65 years of age with overweight or obesity with or without T2D was associated with significantly reduced body weight and HbA1c levels at Week 72 compared with placebo”
Human trial72 weeksn = 616
Obesity pillars
Orforglipron decreases HbA1c in humans (versus dapagliflozin in type 2 diabetes inadequately controlled with metformin).
“At week 40, all OFG doses were superior to DAPA in reducing HbA1c”
Human trialversus dapagliflozin in type 2 diabetes inadequately controlled with metformin3, 12, 36 mg once daily40 weeksn = 962
Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin
ADA Scientific Sessions 2026 abstract
Orforglipron decreases HbA1c in humans (add-on to titrated insulin glargine) (1.54 to 2.05% vs 0.77% with placebo).
“Mean HbA1c decreased by 1.54 to 2.05% in the OFG groups vs 0.77% with PBO.”
Human trialadd-on to titrated insulin glargine40 weeksn = 546
ADA Scientific Sessions 2026 abstract
Orforglipron decreases HbA1c in humans (type 2 diabetes inadequately controlled with metformin; versus semaglutide 7 mg) (-0.48 percentage points versus semaglutide 7 mg (95% CI -0.65 to -0.31; p<0.0001)).
“Estimated treatment differences were -0·48% (95% CI -0·65 to -0·31; p<0·0001) for orforglipron 12 mg versus semaglutide 7 mg”
Human trialtype 2 diabetes inadequately controlled with metformin; versus semaglutide 7 mgoral12 mg once daily52 weeks
Lancet (London, England)
Orforglipron decreases HbA1c in humans (type 2 diabetes and/or obesity; compared with placebo) (MD −1.07%, 95% CI −2.00 to −0.13).
“Orforglipron reduced HbA1c (primary MD –1.07%, 95% CI –2.00 to –0.13;”
Reviewtype 2 diabetes and/or obesity; compared with placebon = 2,672
AHA Scientific Sessions 2026 abstract
Orforglipron improves HbA1c in humans (overweight or obesity, with or without type 2 diabetes mellitus).
“Improvements in glycated hemoglobin (HbA1c), fasting glucose, waist circumference, systolic blood pressure, triglycerides, and non-high-density lipoprotein cholesterol were also reported across several studies.”
Reviewoverweight or obesity, with or without type 2 diabetes mellitus
Cureus
Orforglipron decreases HbA1c in phase 3 trials.
“Phase 3 trials demonstrated significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers”
Reviewin phase 3 trials
American journal of nephrology
All 13Fewer
Resistance training
downin humans9no changein humans2−0.6%
10 studies
Resistance training
downin humans9no changein humans2−0.6%
Resistance training decreases HbA1c in humans (type 2 diabetes).
“Additionally, a significant reduction in HbA1c was observed in the training group (P = 0.012)”
Human trialtype 2 diabetes3 sessions per week, 40–75% of one repetition maximum8 weeksfemalesn = 14
Research SquarePreprint
Resistance training decreases HbA1c in humans (MD = −0.41, 95% CI −0.62 to −0.20).
“The meta-analysis suggested that elastic-band resistance training may reduce HbA1c in patients with T2DM.”
Human trial12 weeks (11 trials), 16 weeks, 24 weeks, or 48 weeksn = 618
Frontiers in public health
Resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (MD = -0.41, 95% CI -0.62 to -0.20).
“Elastic-band resistance training was associated with reductions in HbA1c (MD = -0.41, 95% CI -0.62 to -0.20)”
Human trialtype 2 diabetes mellitus
Frontiers in public health
Resistance training decreases HbA1c in Ex + VitD group.
“Within-group analyses showed that the Ex + VitD group exhibited the greatest glycemic improvement, with HbA1c decreasing from 6.61 ± 0.60% to 6.48 ± 0.58% (Δ = −0.13 ± 0.20), fasting glucose from 7.37 ± 1.15 to 6.58 ± 1.10 mmol/L (Δ = −0.79 ± 0.56), insulin from 5.48 ± 4.24 to 3.52 ± 2.14μU/mL (Δ = ±3.55), and HOMA-IR from 1.80 ± 1.41 to 1.03 ± 0.66 (Δ = −0.77 ± 1.14”
Human trialin Ex + VitD group12 weeksn = 15
Metabolites
Resistance training decreases HbA1c in humans (MD = −0.51, 95% CrI [−0.86, −0.15]).
“Resistance training involving approximately 1000 to 2100 repetitions per week represents an effective dose range capable of significantly improving HbA1c levels in overweight or obese patients with T2DM.”
Human trialn = 633
Frontiers in physiology
Resistance training decreases HbA1c in humans (overweight or obese type 2 diabetes) (MD = -0.51, 95% CrI [-0.86, -0.15]).
“1,500 reps/week (MD = -0.51, 95% CrI [-0.86, -0.15])”
Human trialoverweight or obese type 2 diabetes23 weeks
Frontiers in physiology
Resistance training showed no clear effect on HbA1c in humans (older adults with type 2 diabetes and sarcopenia).
“HbA1c showed no clear intervention-related change”
Human trialolder adults with type 2 diabetes and sarcopenia24 weeks
Strength gains waned in seniors with type 2 diabetes and muscle loss
Acta diabetologica
Resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (-0.62%).
“Resistance training also improved glycemic control, reducing hemoglobin A1c by -0.62% and HOMA-IR by -0.90”
Human trialtype 2 diabetes mellitusn = 1,396
Maturitas
Resistance training decreases HbA1c in humans (type 2 diabetes mellitus and frailty) (β=-0.28, 95% CI -0.53% to -0.03%, p=0.03).
“A1C (β=-0.28, 95% CI -0.53% to -0.03%; p=0.03)”
Human trialtype 2 diabetes mellitus and frailty16 weeksn = 182
Canadian journal of diabetes
Resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (MD -0.62, 95% CI -0.93 to -0.30).
“HIRT; MD - 0.62, 95% CI - 0.93 to -0.30), low-certainty evidence indicated that moderate-intensity aerobic training (MIAT; MD - 0.58, 95% CI - 1.10 to -0.05)”
Reviewtype 2 diabetes mellitus
Frontiers in public health
All 13Fewer
Dapagliflozin
downin humans6no changein humans3
9 studies
Dapagliflozin
downin humans6no changein humans3
Dapagliflozin showed no clear effect on HbA1c in humans (Kidney transplant recipients with post-transplant diabetes mellitus; versus standard care).
“whereas HbA1c and tacrolimus trough concentrations were similar.”
Human trialKidney transplant recipients with post-transplant diabetes mellitus; versus standard care10 mg daily54 weeks
Diabetes research and clinical practice
Dapagliflozin decreases HbA1c in humans (as an adjunct to insulin).
“Similarly, Group B demonstrated reductions of 23.6% in FBG, 25.1% in 2hPBG, and 24.9% in HbA1c. FBG, 2hPBG and HbA1c reductions were significantly greater in Group B than in Group A, indicating superior blood glucose index control.”
Human trialas an adjunct to insulin3 months post-dischargen = 90
Clinics (Sao Paulo, Brazil)
Dapagliflozin decreases HbA1c in humans (adjunct to insulin in type 2 diabetes) (24.9% vs. 10.3%).
“Reductions in Group B versus Group A were: HbA1c (24.9%vs. 10.3%)”
Human trialadjunct to insulin in type 2 diabetes3 monthsn = 86
Clinics (Sao Paulo, Brazil)
Dapagliflozin decreases HbA1c in humans (added to semaglutide, Period 2 (weeks 26 to 52), vs placebo) (-0.46% HbA1c vs placebo).
“In Period 2, HbA1c was further reduced by 0.46% (95% CI -0.78, -0.14; p=0.003) by dapagliflozin vs placebo”
Human trialadded to semaglutide, Period 2 (weeks 26 to 52), vs placebooral10 mg daily26 weeksn = 36
ADA Scientific Sessions 2026 abstract
Dapagliflozin showed no clear effect on HbA1c in humans (fell by 0.8% in both groups).
“HbA1c fell by 0.8% in both groups with no between-group difference (p = 0.887), although fasting plasma glucose, fasting insulin, and HOMA2 dropped significantly in dapagliflozin arm..”
Human trial12 weeksn = 98
Cardiovascular diabetology
Dapagliflozin showed no clear effect on HbA1c in humans (type 2 diabetes) (between-group p = 0.887).
“glycemic control improved similarly in both groups (median [IQR] HbA1c change: -0.78 [0.11]% vs. -0.80 [0.10]%; between-group p = 0.887).”
Human trialtype 2 diabetes12 weeksn = 96
Cardiovascular diabetology
Dapagliflozin decreases HbA1c in humans (type 2 diabetes; compared with placebo) (-0.52 vs. 0.11; p = 0.012).
“dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015), and HbA1c (-0.52 vs. 0.11, p = 0.012).”
Human trialtype 2 diabetes; compared with placebo10 mg12 monthsn = 56
Obesity (Silver Spring, Md.)
Dapagliflozin showed no clear effect on HbA1c in humans.
“This indicates that HbA1c levels decreased significantly throughout the treatment period regardless of the therapeutic regimen employed, yet no differences were observed between the three treatment groups in their efficacy or rate of HbA1c reduction.”
Human trialn = 81
Journal of diabetes research
Dapagliflozin is linked with lower HbA1c in humans (-0.91 ± 1.78% points).
“HbA1c showed a reduction of 0.91 ± 1.78% points among 158 patients with paired HbA1c data (paired p < 0.001)”
Humansn = 158
Scientific reports
Dapagliflozin is linked with lower HbA1c in humans (compared with matched controls, whose HbA1c fell from 8.18% to 7.80%) (8.10% to 7.10% vs 8.18% to 7.80% in controls).
“HbA1c decreased from 8.10% (65 mmol/mol) to 7.10% (54 mmol/mol) in the dapagliflozin group”
Humanscompared with matched controls, whose HbA1c fell from 8.18% to 7.80%10 mg/day12 monthsn = 30
Acta diabetologica
All 11Fewer
Exercise
downin humans7upin humans1−23% to −0.4%
8 studies
Exercise
downin humans7upin humans1−23% to −0.4%
Exercise decreases HbA1c in humans (d = 1.02).
“Glycemic indices were significantly improved with a reduction of fasting glucose of 12.82mg/dl and a reduction in the HbA1c of 0.42 percentage points, which practically shifted the group mean to the normoglycemic range (HbA1c 5.76%).”
Human trial12 weeksmalesn = 30
Research SquarePreprint
Exercise decreases HbA1c in humans (sedentary, overweight or obese men) (-0.42%).
“fasting glucose (−12.82 mg/dL), and HbA1c (−0.42%) (all p ≤ 0.002).”
Human trialsedentary, overweight or obese men12 weeksmalesn = 15
Research SquarePreprint
Exercise improves HbA1c in adults with type 2 diabetes (from 72% to 79% (P=0.02)).
“The proportion of individuals achieving targets increased from 72% to 79% (P=0.02) for A1c”
Human trialin adults with type 2 diabetes12-week
ADA Scientific Sessions 2026 abstract
Exercise decreases HbA1c in humans (young-onset T2DM) (F = 8.23, p < 0.001).
“also in HbA1c (F = 8.23, p <0.001) and FBG (F = 3.44, p <0.034) after 12 and 24 weeks, respectively.”
Human trialyoung-onset T2DM12-weekn = 84
Current medical research and opinion
Exercise decreases HbA1c in humans (metabolic syndrome) (-22.8%).
“After 3 months, the CT group showed significant improvements compared to controls in blood glucose (-36.4%), HbA1c (-22.8%), HOMA-IR (-12.5%)”
Human trialmetabolic syndrome3 monthsfemales
Biology of sport
Exercise decreases HbA1c in humans (type 2 diabetes; compared with nonexercise control) (−0.32 percentage points).
“HbA1c was reduced by 0.32 percentage points (seven trials; I 2 = 0%)”
Reviewtype 2 diabetes; compared with nonexercise controlstructured exercise≥ 4 weeks
Geriatrics & gerontology international
Exercise decreases HbA1c in humans (long-term studies) (MD -0.11%, 95% CI -0.19 to -0.03).
“morning training was associated with a greater reduction in HbA1c (mean difference [MD] - 0.11%, 95% confidence intervals [CI] - 0.19 to - 0.03, I2 = 0%, p = 0.009)”
Reviewlong-term studies
Sports medicine - open
Exercise decreases HbA1c in humans (adults with type 1 diabetes) (MD -0.39 (-0.64, -0.15), P=0.002).
“exercise training had a statistically significant reduction in HbA1c [mean difference (MD), confidence interval (CI)]: -0.39 (-0.64, -0.15), P=0.002, I2=0%”
Reviewadults with type 1 diabetes
Cell journal
Exercise decreases HbA1c in patients with type 1 diabetes (WMD = -0.52, 95% CI = [-0.74, -0.29]).
“Results showed exercise had significant effect on reducing Glycated Hemoglobin (HbA1c) (WMD = -0.52; 95% CI = [-0.74, -0.29]).”
Reviewin patients with type 1 diabetesn = 452
Diabetes, metabolic syndrome and obesity : targets and therapy
Time-restricted feeding
downin humans7no changein humans1−0.8%
8 studies
Time-restricted feeding
downin humans7no changein humans1−0.8%
Time-restricted feeding decreases HbA1c in veterans with spinal cord injury and obesity (-0.2 ± 0.1%).
“Twenty-four-hour glucose levels decreased by 7 ± 3 mg/dL (p = 0.02) and the GMI decreased by 0.2 ± 0.1% (p = 0.02), both with large effect sizes (d ~0.8).”
Human trialin veterans with spinal cord injury and obesity6-week
Nutrients
Time-restricted feeding decreases HbA1c in humans (veterans with spinal cord injury and obesity) (-0.2 ± 0.1%, p = 0.02).
“Glucose Management Indicator (GMI), which estimates average HbA1c levels (-0.2 ± 0.1%, p = 0.02)”
Human trialveterans with spinal cord injury and obesity6-weekn = 14
Nutrients
Time-restricted feeding decreases HbA1c in humans (compared with general diet in overweight or obese adults with type 2 diabetes) (MD = -0.55, 95% CI: -0.77 to -0.33).
“Compared with GD, TRE significantly reduced HbA1c (MD = -0.55, 95% CI: -0.77 to -0.33) and total cholesterol (MD = -0.17 mmol/L, 95% CI: -0.19 to -0.14).”
Human trialcompared with general diet in overweight or obese adults with type 2 diabetesn = 805
Frontiers in nutrition
Time-restricted feeding decreases HbA1c in humans.
“Following 3 months of TRE (target: 10 hours, 9:00 am-7:00 pm), her eating window was shortened to 9.86 hours (9:03 am - 6:55 pm), and her HbA1c decreased from 7.7% to 7.3%.”
Human trial3 months
Frontiers in clinical diabetes and healthcare
Time-restricted feeding decreases HbA1c in humans (compared to the CR group in adults with type 1 diabetes) (-0.46% [95% CI, -0.80, -0.12], P = 0.01).
“HbA1c levels were significantly reduced by the TRE group when compared to the CR group (-0.46% [95% CI, -0.80, -0.12], P = 0.01).”
Human trialcompared to the CR group in adults with type 1 diabeteseating only between 12-8 pm, without calorie counting6 monthsn = 32
ADA Scientific Sessions 2026 abstract
Time-restricted feeding showed no clear effect on HbA1c in humans (MD 0.04%, 95% CI -0.20 to 0.27).
“No significant between-group differences were observed for HbA1c (MD 0.04%, 95% CI -0.20 to 0.27; P=0.75; I 2 =0%)”
ReviewCompared with caloric restriction in adults with overweight, obesity, or cardiometabolic risk factors4–52 weeks
AHA Scientific Sessions 2026 abstract
Time-restricted feeding decreases HbA1c in one longitudinal cohort (-0.78%).
“A persistent HbA1c reduction of -0.78% at 18 months in one longitudinal cohort suggested that glycemic benefits may compound with sustained adherence.”
Reviewin one longitudinal cohort18 months
Clinical medicine insights. Endocrinology and diabetes
Time-restricted feeding decreases HbA1c in humans (type 2 diabetes) (MD: -0.32%, 95% CI: -0.47 to -0.18).
“TRE significantly reduced HbA1c (MD: -0.32%, 95% CI: -0.47 to -0.18) and fasting blood glucose (MD: -0.44 mmol/L, 95% CI: -0.68 to -0.19).”
Reviewtype 2 diabetes
Diabetology & metabolic syndrome
Time-restricted feeding decreases HbA1c in humans (compared with control) (WMD: -0.25% (95% CI -0.44 to -0.05)).
“HbA1c (%) [WMD: -0.25% (95% CI -0.44 to -0.05), p = 0.01]”
Reviewcompared with control
Reviews in endocrine & metabolic disorders
High-intensity interval training
downin humans6
6 studies
High-intensity interval training
downin humans6
High-intensity interval training decreases HbA1c in humans.
“For the primary outcome, HbA1c levels decreased significantly from baseline to post-intervention in both the HIIT and MICT groups (both p = 0.001).”
Human trial12 weeksn = 12
Journal of clinical medicine
High-intensity interval training decreases HbA1c in bypass surgery patients (mean reduction of 7.71%).
“with the HIIT-bypass group showing significant improvements in HbA1c, insulin, and FBS (mean reduction of 7.71%, 24.98%, and 6.34%, respectively; p < .05).”
Human trialin bypass surgery patients8 weeksfemalesn = 20
BMC musculoskeletal disorders
High-intensity interval training decreases HbA1c in older adults with T2DM (MD = -0.95%).
“HIIT demonstrated the largest estimated reduction (MD = -0.95%; 95% CrI -1.45, -0.49)”
Reviewin older adults with T2DM
Diabetes research and clinical practice
High-intensity interval training decreases HbA1c in humans (type 2 diabetes mellitus) (MD = −1.02% (95% CrI −1.48, −0.59)).
“high-intensity interval training (HIIT) produced the largest HbA1c reduction versus minimal-intervention control (MD = −1.02%; 95% CrI −1.48, −0.59).”
Reviewtype 2 diabetes mellitus
ADA Scientific Sessions 2026 abstract
High-intensity interval training decreases HbA1c in humans (type 2 diabetes mellitus; compared with control) (-0.70 percentage points (95% CI -0.88 to -0.51)).
“and reduced glycosylated hemoglobin by 0.70% (95% confidence interval -0.88 to -0.51).”
Reviewtype 2 diabetes mellitus; compared with control
Clinical rehabilitation
High-intensity interval training decreases HbA1c in humans (adults with type 1 diabetes) (MD -0.24 (-0.45, -0.02), P=0.03).
“statistically significant effect of high-intensity interval training (HIIT) on HbA1c levels in both the within-group analyses [MD: -0.24 (-0.45, -0.02), P=0.03, I2=0%]”
Reviewadults with type 1 diabetes
Cell journal
Metformin
downin humans5
5 studies
Metformin
downin humans5
Metformin decreases HbA1c in humans (Prediabetes and body mass index ≥23 kg/m2).
“a significant reduction in HbA1c was observed only in the MET group.”
Human trialPrediabetes and body mass index ≥23 kg/m26 monthsn = 217
Diabetes & metabolism journal
Metformin is linked with lower HbA1c in humans (Newly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication) (6.85% versus 7.29% at baseline).
“The HbA1c level significantly reduced after the 12-week treatment period (6.85% vs 7.29% at baseline, P = .001).”
HumansNewly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication12 weeksn = 68
Medicine
Metformin is linked with lower HbA1c in humans (newly diagnosed type 2 diabetes) (median 7.8 to 7.2; p = 0.001).
“The HbA1c level decreased from 7.8 (6.9-8.9) to 7.2 (6.5-8.1) (p = 0.001).”
Humansnewly diagnosed type 2 diabetessix monthsn = 52
Cureus
Metformin is linked with lower HbA1c in humans (at imeglimin initiation in type 2 diabetes) (adjusted difference -0.57%, 95% CI -0.88 to -0.26).
“Metformin continuation remained associated with greater adjusted HbA1c reduction in sensitivity ANCOVA (adjusted difference - 0.57%, 95% CI - 0.88 to - 0.26; P = 0.0006).”
Humansat imeglimin initiation in type 2 diabetes24 weeksn = 70
Acta diabetologica
Metformin decreases HbA1c in humans (MD -0.070%).
“At 12 months, metformin significantly reduced waist circumference (MD -1.12 cm; p = 0.014), HbA1c (MD -0.070%; p = 0.029)”
ReviewAdded to androgen-deprivation therapy in prostate cancer, versus androgen-deprivation therapy alone12 months
Prostate cancer and prostatic diseases
Liraglutide
downin humans4−0.3%
4 studies
Liraglutide
downin humans4−0.3%
Liraglutide decreases HbA1c in humans (median -2.5% (range, 1.1–3.1%)).
“After 12 weeks of therapy, the median HbA1c decreased by 2.5% (27 mmol/mol; range, 1.1–3.1% [12–34 mmol/mol]; p = 0.012”
Human trial12 weeksn = 5
Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes
Frontiers in endocrinology
Liraglutide decreases HbA1c in humans (congenital generalized lipodystrophy; treatment completers) (Median change, -2.5%).
“liraglutide significantly reduced HbA1c (median change, -2.5%; p=0.012)”
Human trialcongenital generalized lipodystrophy; treatment completers1.8 mg/day12 weeksn = 5
Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes
Frontiers in endocrinology
Liraglutide decreases HbA1c in humans.
“compared with controls, the total effective rate of the research group was increased, Ca, BALP and SFRP5 were elevated and the post-medication P, β-CTX, GM indices, glycemic variability parameters and inflammatory markers were decreased”
Human trialin diabetic osteoporosis patients receiving zoledronic acid and calcium carbonate and vitamin D3n = 99
American journal of translational research
Liraglutide is linked with lower HbA1c in humans (Type 2 diabetes and obesity; compared with SGLT-2 inhibitors) (0.4% greater HbA1c reduction (95% CI: 0.3–0.5)).
“liraglutide and dulaglutide provided superior glycaemic control and similar weight reduction over 5 years”
HumansType 2 diabetes and obesity; compared with SGLT-2 inhibitors18 months; advantage maintained throughout follow-upn = 4,296
Diabetes, obesity & metabolism
Liraglutide decreases HbA1c in humans (versus glucose-lowering therapies (GLTs)) (-0.26%).
“while liraglutide 1.8 mg reduced HbA1c by -0.26% versus GLTs”
Reviewversus glucose-lowering therapies (GLTs)1.8 mg1.8 mg
Diabetes, metabolic syndrome and obesity : targets and therapy
Icosema
downin humans3no changein humans1
4 studies
Icosema
downin humans3no changein humans1
Icosema showed no clear effect on HbA1c in humans (versus insulin-based intensification in adults inadequately controlled on basal insulin) (pooled MD -0.37%, 95% CI -0.95 to 0.21; I2=98%).
“IcoSema showed no statistically significant difference in HbA1c reduction compared with control (pooled MD -0.37%, 95% CI -0.95 to 0.21; P = 0.21; I2=98%)”
Human trialversus insulin-based intensification in adults inadequately controlled on basal insulin
Cardiovascular diabetology. Endocrinology reports
Icosema decreases HbA1c in humans (versus once-daily insulin glargine U100) (ETD -0.88 percentage points (95% CI -1.12 to -0.63)).
“mean change to week 40 was greater with IcoSema versus glargine U100 (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63])”
Human trialversus once-daily insulin glargine U100once-weeklyweek 40n = 485
The lancet. Diabetes & endocrinology
Icosema decreases HbA1c in humans (versus basal insulin alone) (-0.74 percentage points (95% CI -0.95 to -0.53)).
“Against basal insulin alone (COMBINE 1 and 4; two trials, 1,776 participants), IcoSema lowered HbA1c by 0.74 percentage points (95% confidence interval (CI) -0.95 to -0.53; I2 = 63%)”
Reviewversus basal insulin alonen = 1,776
IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis
Cureus
Icosema decreases HbA1c in humans (compared with IDegLira) (-0.4% (95% CrI -0.56, -0.24)).
“compared with IDegLira, IcoSema was associated with significantly greater HbA1c reduction (- 0.4%; 95% credible interval [CrI] - 0.56, - 0.24)”
Reviewcompared with IDegLira52 weeks
Diabetes therapy : research, treatment and education of diabetes and related disorders
Combined aerobic and resistance training
downin humans4
4 studies
Combined aerobic and resistance training
downin humans4
Combined aerobic and resistance training decreases HbA1c in humans (older adults with type 2 diabetes mellitus) (MD = -1.05%).
“For HbA1c, CE (MD = -1.05%; 95% CrI: -1.43, -0.64), TCS (MD = -0.80%; 95% CrI: -1.09, -0.52), HIIT (MD = -0.63%; 95% CrI: -1.07, -0.19)”
Human trialolder adults with type 2 diabetes mellitus
Frontiers in endocrinology
Combined aerobic and resistance training decreases HbA1c in older adults with T2DM (MD = -0.59%).
“followed by CE (MD = -0.59%; 95% CrI -0.93, -0.25)”
Reviewin older adults with T2DM
Diabetes research and clinical practice
Combined aerobic and resistance training decreases HbA1c in humans (compared with control conditions) (Hedges' g = -0.44, p < 0.01).
“Compared with control conditions, combined training significantly improved HbA1c (Hedges' g = -0.44, p < 0.01)”
Reviewcompared with control conditionsn = 1,853
Maturitas
Combined aerobic and resistance training decreases HbA1c in humans (type 2 diabetes mellitus) (MD = −0.60% (95% CrI −0.94, −0.26)).
“combined exercise (CE) (MD = −0.60%; 95% CrI −0.94, −0.26)”
Reviewtype 2 diabetes mellitus
ADA Scientific Sessions 2026 abstract
Physical activity
downin humans3no changein humans1
3 studies
Physical activity
downin humans3no changein humans1
Physical activity decreases HbA1c in humans (−1.18% vs −0.57%).
“HbA1c dropped by 0.57% in the control group, with a greater 1.18% reduction (95% CI, −1.65, −0.71) in the intervention group (ηp2 = 0.179).”
Human trial12 weeksn = 28
Pilot and feasibility studies
Physical activity decreases HbA1c in humans (newly diagnosed with AGT) (-1.18% (95% CI, -1.65, -0.71)).
“participants in the intervention group demonstrated a 1.18% reduction in HbA1c (95% CI, -1.65, -0.71)”
Human trialnewly diagnosed with AGTaverage of 77 min daily12-week
Pilot and feasibility studies
Physical activity showed no clear effect on HbA1c in humans (β = −0.39%, 95% CI: - 1.6 to 0.8).
“The interaction for HbA1c (β = −0.39%, 95% CI: - 1.6 to 0.8) suggested a modest differential change, while time effects for both FPG ((β = −11.1, 95% CI: −17.1 to −5.1) and HbA1c (β = −1.7%, 95% CI: −2.6 to −0.7) pointed toward reductions in glycemic levels across both groups”
Human trial12-weekn = 28
Global epidemiology
Physical activity decreases HbA1c in humans (abnormal glucose tolerance) (-1.2% vs. -0.6%).
“The intervention group was associated with larger within-group changes in HbA1c (-1.2% vs. -0.6%)”
Human trialabnormal glucose tolerance12-weekn = 28
Global epidemiology
Physical activity is linked with lower HbA1c in people with type 2 diabetes (6.84% vs. 8.07%, p<0.0001).
“Physically active participants exhibited lower HbA1c (6.84% vs. 8.07%, p<0.0001)”
Humansin people with type 2 diabetesn = 185
Georgian medical news
All 218Fewer
Effects
32Mortality
mediatesin humans2no changein humans2
4 studies
Mortality
mediatesin humans2no changein humans2
HbA1c is linked with mortality in dynapenic obesity-mortality association (13.7% (P = 0.006)).
“SII and HbA1c statistically explained 5.8% (P = 0.041) and 13.7% (P = 0.006), respectively, of the observed dynapenic obesity-mortality association.”
Humansin dynapenic obesity-mortality associationn = 5,674
Archives of gerontology and geriatrics
HbA1c is linked with mortality in humans (association between cumulative RCII burden and all-cause mortality) (4.61% of the effect).
“Mediation analyses indicated that Cystatin C and HbA1c significantly mediated this association, accounting for 10.71% and 4.61% of the effect, respectively.”
Humansassociation between cumulative RCII burden and all-cause mortalityn = 6,977
Geriatrics & gerontology international
HbA1c was not clearly linked with mortality in acute coronary syndrome patients (2.0% vs 1.6% vs 2.9%, p = 0.294).
“In-hospital mortality showed a gradual increase across these groups: 2.0% in non-diabetics, 1.6% in pre-diabetics, and 2.9% in diabetics (p = 0.294).”
Humansin acute coronary syndrome patientsin-hospitaln = 2,772
Prediabetes in acute coronary syndrome: an overlooked predictor of adverse outcomes
Frontiers in clinical diabetes and healthcare
HbA1c was not clearly linked with mortality in humans (hospitalized patients with type 2 diabetes) (p = 0.615).
“HbA1c levels were not significantly associated with mortality (p = 0.615).”
Humanshospitalized patients with type 2 diabetesn = 372
Medicina (Kaunas, Lithuania)
Type 2 diabetes
mediatesin humans2
2 studies
Type 2 diabetes
mediatesin humans2
HbA1c is linked with type 2 diabetes in humans (35.9%).
“HbA1c mediated 35.9% of the total effect (p = 0.017)”
Humansserum
Diabetes research and clinical practice
HbA1c is linked with type 2 diabetes in humans (conservative outcome definition) (13.7-27.5%).
“Under the conservative outcome definition, HbA1c mediated 13.7-27.5% of the total effect”
Humansconservative outcome definition
Frontiers in nutrition
Cognitive function
downin humans2
2 studies
Cognitive function
downin humans2
HbA1c is linked with worse cognitive function in humans (type 1 diabetes) (β = -0.47, p < 0.001).
“higher HbA1c (β = -0.47 and p < 0.001) and higher vibration perception threshold (β = -0.049 and p = 0.004) were independent predictors of lower cognitive performance.”
Humanstype 1 diabetes
Diabetes/metabolism research and reviews
HbA1c is linked with worse cognitive function in humans.
“Age and HbA1c were significantly inversely correlated with 3MS scores.”
Humansn = 396
Frontiers in aging
Cardiometabolic multimorbidity
mediatesin humans1
1 study
Cardiometabolic multimorbidity
mediatesin humans1
HbA1c is linked with cardiometabolic multimorbidity in humans (48.44% of the association).
“In CHARLS, exploratory mediation analysis estimated that HbA1c accounted for 48.44% of the association.”
Humansexploratory mediation of the association between TyHGB and cardiometabolic multimorbidity in CHARLSn = 8,116
Frontiers in endocrinology
8-hydroxy-2'-deoxyguanosine
no changein humans1
1 study
8-hydroxy-2'-deoxyguanosine
no changein humans1
HbA1c was not clearly linked with 8-hydroxy-2'-deoxyguanosine in humans (patient subgroups defined by HbA1c).
“Stratification of patients according to HbA1c levels revealed no statistically significant differences in 8-OHdG concentrations among the subgroups.”
Humanspatient subgroups defined by HbA1cplasma
Plasma 8-Hydroxy-2′-Deoxyguanosine Levels in Patients with Type 2 Diabetes Mellitus
Diagnostics (Basel, Switzerland)
Brain 18F-FDG uptake
no changein humans1
1 study
Brain 18F-FDG uptake
no changein humans1
HbA1c was not clearly linked with brain 18F-FDG uptake in humans.
“Linear regression to HbA1c showed a negative correlation to 18F-FDG uptake in frontal and parietal cortical subregions, but no correlation to temporal lobe uptake.”
Humanstemporal lobe
Effect of metformin treatment on brain 18F-FDG uptake: a translational study
Frontiers in radiology
High-sensitivity cardiac troponin T
no changein humans1
1 study
High-sensitivity cardiac troponin T
no changein humans1
HbA1c was not clearly linked with high-sensitivity cardiac troponin T in people with prediabetes (r = -0.053).
“No significant association was found between hs-cTnT values and HbA1c levels (Spearman's r = -0.053; p = 0.602).”
Humansin people with prediabetes
PeerJ
Cardiometabolic disease
mediatesin humans1
1 study
Cardiometabolic disease
mediatesin humans1
HbA1c is linked with cardiometabolic disease in humans (between preference-intake discordance and CMD).
“HbA1c was a consistent positive mediator”
Humansbetween preference-intake discordance and CMDn = 168,163
Research SquarePreprint
Early weight-loss response
no changein humans1
1 study
Early weight-loss response
no changein humans1
HbA1c was not clearly linked with early weight-loss response in humans (baseline glycemic characteristics).
“rather than with baseline glycemic or hemodynamic characteristics”
Humansbaseline glycemic characteristics
Preprints.orgPreprint
Cardiometabolic multiple long-term conditions risk discrimination
upin humans1
1 study
Cardiometabolic multiple long-term conditions risk discrimination
upin humans1
HbA1c is linked with better cardiometabolic multiple long-term conditions risk discrimination in humans (added to established risk factors) (ΔC-index=0.0344, P<.001).
“Adding HbA1c to established risk factors improved discrimination (ΔC-index=0.0344, P<.001)”
Humansadded to established risk factors12-15 yearsn = 2,233
Mayo Clinic proceedings. Innovations, quality & outcomes
All 32Fewer
Upstream
13DNAm PAI-1
mediatesin humans1
1 study
DNAm PAI-1
mediatesin humans1
DNAm PAI-1 is linked with HbA1c in humans (28.8% of association mediated; FDR p=0.038).
“DNAm PAI-1 mediated 30.0% of the association with IL-6 (N=232; FDR p=0.030) and 28.8% of the association with HbA1c (N=227; FDR p=0.038).”
HumansAssociation of neighborhood building conditions rated fair or below with HbA1c; adjusted for sex and self-reported racen = 227
AHA Scientific Sessions 2026 abstract
Body mass index
no changein humans1
1 study
Body mass index
no changein humans1
Body mass index was not clearly linked with HbA1c in humans (type 2 diabetes mellitus; comparison across BMI groups) (mean HbA1c ∼ 8.2-8.4% across BMI groups).
“Glycemic control (mean HbA1c ∼ 8.2-8.4%) was similar among BMI groups.”
Humanstype 2 diabetes mellitus; comparison across BMI groupsn = 6,530
Journal of Taibah University Medical Sciences
Anxiety
downin humans1
1 study
Anxiety
downin humans1
Anxiety is linked with lower HbA1c in humans (diabetes in older adults) (β = -0.43, p = 0.003).
“anxiety (β = -0.43, p = 0.003)”
Humansdiabetes in older adults
Homebound status and glycemic control among older adults: results from a national survey
GeroScience
Depression
upin humans1
1 study
Depression
upin humans1
Depression is linked with higher HbA1c in humans (diabetes in older adults) (β = + 0.62, p < .001).
“depression (β = + 0.62, p < .001)”
Humansdiabetes in older adults
Homebound status and glycemic control among older adults: results from a national survey
GeroScience
Homebound status
no changein humans1
1 study
Homebound status
no changein humans1
Homebound status was not clearly linked with HbA1c in humans (diabetes).
“Homebound status was not independently associated with HbA1c in adjusted models.”
Humansdiabetes
Homebound status and glycemic control among older adults: results from a national survey
GeroScience
Second-line glucose-lowering therapy
downin humans1
1 study
Second-line glucose-lowering therapy
downin humans1
second-line glucose-lowering therapy is linked with lower HbA1c in humans (adults aged 70 or younger, 12-month outcome, trend 2019 to 2023) (-11.3 to -12.9 mmol/mol).
“mean 12-month HbA1c response improved from -11.3 mmol/mol (95% CI: -11.6 to -11.0) in 2019 to -12.9 mmol/mol”
Humansadults aged 70 or younger, 12-month outcome, trend 2019 to 202312 monthsn = 84,589
Diabetes, obesity & metabolism
Depressive symptoms
no changein humans1
1 study
Depressive symptoms
no changein humans1
Depressive symptoms were not clearly linked with HbA1c in humans (Chinese middle-aged and older adults) (β2 = 0.001 (95% CI -0.005 to 0.003, p = 0.6442)).
“path coefficient from baseline CES-D to follow-up HbA1c (β2, 0.001; 95% CI, -0.005 to 0.003; p = 0.6442)”
HumansChinese middle-aged and older adultsn = 7,124
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Vitamin D deficiency
no changein humans1
1 study
Vitamin D deficiency
no changein humans1
vitamin D deficiency was not clearly linked with HbA1c in humans (type 2 diabetes mellitus).
“but not with fasting plasma glucose or HbA1c.”
Humanstype 2 diabetes mellitusn = 302
Association between vitamin D deficiency and sarcopenia in older adults with type 2 diabetes
Vietnam Journal of Diabetes and Endocrinology
PIEZO1
downin humans1
1 study
PIEZO1
downin humans1
PIEZO1 is linked with lower HbA1c in humans (additive genetic model).
“PIEZO1 rs563555492 T was associated with erythrocytic traits and lower HbA1c”
Humansadditive genetic model
medRxivPreprint
HBB
upin humans1
1 study
HBB
upin humans1
HBB is linked with higher HbA1c in humans (rs33950507 heterozygous carriers) (beta=0.13, 95%CI:0.08-0.18, p=7.8x10-8).
“rs33950507, a common variant causal for HbE thalassaemia, was associated with increased HbA1c (beta=0.13, 95%CI:0.08-0.18, p=7.8x10-8)”
Humansrs33950507 heterozygous carriers
medRxivPreprint
All 13Fewer
Associations
228Mortality
upin humans7mixedin humans4downin humans3HR 0.71–1.43
14 studies
Mortality
upin humans7mixedin humans4downin humans3HR 0.71–1.43
HbA1c predicts mortality in humans (diabetes subgroup receiving maintenance hemodialysis; multivariable-adjusted) (Adjusted HR 1.43 per 1% higher HbA1c, 95% CI 1.17–1.76).
“Within the diabetes subgroup, HbA1c was the strongest modifiable predictor (adjusted HR 1.43 per 1%, 95% CI 1.17–1.76, p < 0.001)”
Humansdiabetes subgroup receiving maintenance hemodialysis; multivariable-adjusted68 monthsn = 126
PloS one
HbA1c is associated with mortality in humans (Patients without previously diagnosed diabetes who underwent coronary angiography).
“HbA1c showed a U-shaped association with fatal outcomes, namely cardiovascular death and all-cause mortality”
HumansPatients without previously diagnosed diabetes who underwent coronary angiographyMedian follow-up 5.1 yearsn = 55,570
ESC Congress 2026 abstract
HbA1c is linked with a higher risk of mortality in humans (cystic fibrosis-related diabetes) (RR 1.41 (95% CI 1.15-1.73)).
“Compared with HbA1c ≤42 mmol/mol, adjusted mortality rate ratios were 1.41 (95% CI 1.15-1.73) for HbA1c >42-53 mmol/mol”
Humanscystic fibrosis-related diabetesn = 4,477
Diabetes care
HbA1c is associated with mortality in humans (Type 2 diabetes with a low incidence of severe hypoglycemia) (Suggested HbA1c target < 6.5%).
“no clear lower threshold of the glycated hemoglobin associated with the lowest risk of myocardial infarction or all-cause mortality”
HumansType 2 diabetes with a low incidence of severe hypoglycemia
PloS one
HbA1c is associated with mortality in humans (Adults with diabetes; baseline HbA1c ≥ 7.0% versus < 7.0%) (Adjusted OR 2.28, 95% CI 1.15–4.59).
“HbA1c ≥ 7.0% was associated with higher mortality odds than HbA1c < 7.0% (adjusted OR 2.28, 95% CI 1.15–4.59, P = 0.018).”
HumansAdults with diabetes; baseline HbA1c ≥ 7.0% versus < 7.0%2011–2020n = 578
Research SquarePreprint
HbA1c is associated with mortality in humans (General population; U-shaped association).
“We observed a significant non-linear U-shaped association between baseline HbA1c levels and mortality.”
HumansGeneral population; U-shaped associationAverage follow-up of 99.7 ± 53.6 monthsn = 38,072
Non-Linear U-Shaped Trend Associations between HbA1c and All-Cause and Cardiovascular Mortality
Clinical laboratory
HbA1c is linked with a higher risk of mortality in patients with type 2 diabetes on peritoneal dialysis (HR 1.18, 95% CI 1.03-1.35).
“Compared with HbA1C≤8%, HbA1C>8% was associated with higher risk of all-cause mortality in the cohort as a whole (HR 1.18 p=0.02 95%CI 1.03-1.35)”
Humansin patients with type 2 diabetes on peritoneal dialysis
Clinical journal of the American Society of Nephrology : CJASN
HbA1c predicts mortality in humans (HR 1.24 per 1 SD).
“HbA1c (1.24) and albumin (0.81) carried most of the signal”
Humansper 1 SDmedian 4.4 yearsn = 2,144
Research squarePreprint
HbA1c is linked with a lower risk of mortality in humans (HR 0.71; 95% CI, 0.60-0.84).
“reducing the risk of dementia (HR 0.64; 95% CI, 0.51-0.79) and mortality (HR 0.71; 95% CI, 0.60-0.84).”
Humanstrajectory improvement in patients with Poor baseline control (≥9.0%) after SGLT2 inhibitor initiation
HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia
Journal of Alzheimer's disease : JAD
HbA1c is associated with mortality in humans across all frailty groups (lowest at HbA1c 48-57.9 mmol/mol).
“All-cause mortality risk was lowest at HbA1c 48-57.9 mmol/mol and increased at both lower and higher HbA1c levels across all frailty groups.”
Humansacross all frailty groups
Age and ageing
All 14Fewer
Sarcopenia
upin humans6mixedin humans1OR 1.88–1.89
7 studies
Sarcopenia
upin humans6mixedin humans1OR 1.88–1.89
HbA1c is associated with sarcopenia in humans (Type 2 diabetes mellitus for at least 12 months; multivariable analysis) (aOR 1.567, 95% CI 1.004–2.445).
“higher mean HbA1c (aOR 1.567, 95% CI: 1.004–2.445; p = 0.048) were associated with greater odds of sarcopenia”
HumansType 2 diabetes mellitus for at least 12 months; multivariable analysisMean HbA1c over the preceding yearn = 100
Research SquarePreprint
Sarcopenia is associated with HbA1c in humans (male individuals with type 2 diabetes and clinically significant liver fibrosis) (8.8% vs. 7.9%, p = 0.007).
“glycated hemoglobin (HbA1c, 8.8% vs. 7.9%, p = 0.007)”
Humansmale individuals with type 2 diabetes and clinically significant liver fibrosismalesn = 131
Journal of frailty, sarcopenia and falls
HbA1c is associated with sarcopenia in humans (HbA1c ≥ 7.0%) (aOR 3.24, 95% CI 1.42-7.40).
“and those with HbA1c ≥ 7.0% (aOR 3.24, 95% CI 1.42-7.40)”
HumansHbA1c ≥ 7.0%
Glycated Hemoglobin, Lifestyle, and Sarcopenia in Rural Older Adults: A Cross-Sectional Analysis
Nursing & health sciences
HbA1c is linked with a higher risk of sarcopenia in humans (OR 1.89, 95% CI 1.16-3.08).
“poor glycaemic control (HbA1c ≥ 7.0%; OR 1.89, 95% CI 1.16-3.08) were associated with higher odds of sarcopenia.”
Humans
Australasian journal on ageing
HbA1c is associated with sarcopenia in humans.
“associations with composite sarcopenia vary according to diagnostic frameworks and phenotype composition.”
Reviewtype 2 diabetes mellitus; associations depend on diagnostic frameworks and phenotype compositionskeletal muscle
Frontiers in endocrinology
HbA1c is associated with sarcopenia in humans (patients with type 2 diabetes) (OR=1.88, 95%CI 1.36~2.60).
“HbA1c (OR=1.88, 95%CI 1.36~2.60), sex (OR=1.61, 95%CI 1.34~1.92), duration of diabetes (OR=1.23, 95%CI 1.06~1.42), and diabetes complications (OR=4.22, 95%CI 3.29~5.41) were risk factors for sarcopenia”
Reviewpatients with type 2 diabetes
Systematic review of risk prediction models for sarcopenia in patients with type 2 diabetes
Chinese Journal of Geriatric Care
HbA1c is associated with sarcopenia in older patients with type 2 diabetes mellitus.
“higher fasting blood glucose levels, higher HbA1c levels”
Reviewin older patients with type 2 diabetes mellitus
Factors associated with sarcopenia in elderly patients with type 2 diabetes mellitus
Frontiers in endocrinology
Diabetes mellitus
upin humans3upin silico1
4 studies
Diabetes mellitus
upin humans3upin silico1
HbA1c predicts diabetes mellitus in humans (Optimal cut-off 6.1%: sensitivity 89.8%, specificity 86.9%; agreement κ = 0.76).
“For diabetes, HbA1c ≥6.5% showed 75.9% sensitivity and 96.3% specificity, whereas the optimal cut-off was 6.1% (89.8% sensitivity, 86.9% specificity).”
HumansDiagnostic classification relative to oral glucose tolerance test in participants without prior diabetesn = 376
Beyond Global Cut-offs: The Predictive Value of Glycated Haemoglobin for Dysglycaemia in South Asia
Indian journal of endocrinology and metabolism
HbA1c predicts diabetes mellitus in humans (detection of diabetes mellitus) (AUC 0.86 (95% CI: 0.83-0.88)).
“For the diagnosis of DM, HbA1c demonstrated an AUC of 0.86 (95% CI: 0.83-0.88).”
Humansdetection of diabetes mellitusbloodn = 1,162
BMC geriatrics
HbA1c predicts diabetes mellitus in silico.
“SHAP analysis identified HbA1c level, blood glucose level, and age as the most influential predictors”
In silico
Journal of personalized medicine
HbA1c predicts diabetes mellitus in humans (for diabetes detection) (AUC 0.73 to 0.970).
“Reported HbA1c sensitivity ranged from 45.5% to 89.4%, specificity from 80.0% to 100%, and area under the curve (AUC) from 0.73 to 0.970.”
Reviewfor diabetes detection
Journal of Scientific Research and Reports
Cognitive impairment
upin humans4OR 1.53
4 studies
Cognitive impairment
upin humans4OR 1.53
HbA1c is linked with a higher risk of cognitive impairment in humans (coefficient −0.16, 95% CI −0.23, −0.09).
“Higher HbA1c was associated with shorter time to ADRD (coefficient −0.09; 95% CI −0.16, −0.02) and cognitive impairment (−0.16; 95% CI −0.23, −0.09)”
Humansn = 4,571
Journal of dementia and Alzheimer's disease
HbA1c predicts cognitive impairment in humans (inpatients with diabetes mellitus; cognitive impairment assessed by MMSE and MoCA) (AUC 0.743 (MMSE) and 0.778 (MoCA)).
“HbA1c had the best predictive ability for SGNT, with AUCs of 0.743 (MMSE) and 0.778 (MoCA).”
Humansinpatients with diabetes mellitus; cognitive impairment assessed by MMSE and MoCAn = 87
Study of cognitive impairment and diabetes control in older patients with diabetes
Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế
HbA1c is associated with cognitive impairment in humans (type 2 diabetes mellitus) (OR = 1.53, 95% CI: 1.01-2.30).
“HbA1c (OR = 1.53, 95% CI: 1.01-2.30, P = 0.043)”
Humanstype 2 diabetes mellitus
Frontiers in neuroscience
HbA1c predicts cognitive impairment in humans (type 2 diabetes).
“Higher HbA1c levels, glucose variability, severe hypoglycemia, vascular complications, and inflammatory/metabolic markers significantly predicted higher cognitive impairment risk.”
Reviewtype 2 diabetes
Biological research for nursing
Age
upin humans2no changein humans1mixedin humans1OR 1.05
4 studies
Age
upin humans2no changein humans1mixedin humans1OR 1.05
Age predicts HbA1c in humans (recurrent acute coronary syndrome) (OR 1.05, p = 0.040).
“of HbA1c goal (OR 1.05, p = 0.040).”
Humansrecurrent acute coronary syndrome
Genetics and Molecular Research
Age is associated with HbA1c in humans (type 1 or 2 diabetes) (r = 0.113, P = 0.097).
“correlation between age and HbA1c was positive but not statistically significant (r = 0.113, P = 0.097)”
Humanstype 1 or 2 diabetes
Journal of family medicine and primary care
Age is associated with HbA1c in humans (Adjusted linear regression).
“Adjusted linear regression showed a significant association between age and HbA1c (p < 0.001)”
HumansAdjusted linear regressionn = 911
Association between HbA1c chairside values and periodontitis
Journal of dentistry
Age is associated with HbA1c in humans (r = 0.284, p = 0.007).
“A statistically significant but weak positive correlation was observed between age and HbA1c levels (r =0.284, p = 0.007).”
Humansfemalesn = 129
The Pan African medical journal
Semaglutide
downin humans4
4 studies
Semaglutide
downin humans4
Semaglutide is associated with HbA1c in humans (type 2 diabetes) (7.75 ± 1.01% to 6.80 ± 0.88%; p < 0.00001).
“HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001).”
Humanstype 2 diabetesoral12 monthsn = 81
Endocrines
Semaglutide is associated with HbA1c in humans (type 2 diabetes mellitus) (Median HbA1c from 8.9% to 7.8%; BMI from 34.8 to 32.6 kg/m2).
“patients' median HbA1c was reduced from 8.9% [8.4 - 9.9] to 7.8% [7.2 - 8.4] (p < 0.0001)”
Humanstype 2 diabetes mellitus12 monthsn = 186
Frontiers in clinical diabetes and healthcare
Semaglutide is associated with HbA1c in humans (Type 2 diabetes mellitus; initiated at hospital discharge after acute coronary syndrome) (64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol).
“HbA1c improved from 64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol.”
HumansType 2 diabetes mellitus; initiated at hospital discharge after acute coronary syndromeinjectable or orallowest dose108 ± 39 days73% malesn = 60
Use of semaglutide after acute coronary syndrome: an exploratory retrospective study
Journal of cardiovascular medicine (Hagerstown, Md.)
Semaglutide is associated with HbA1c in humans (coexisting hypothyroidism and type 2 diabetes mellitus) (HbA1c −6.7%; BMI −4.04%; triglycerides −6.7%; HDL-C +9%).
“At 6 months, mean HbA1c decreased by 6.7% (P < 0.001)”
Humanscoexisting hypothyroidism and type 2 diabetes mellitusfinal dose = 14 mg daily6 monthsn = 51
Journal of medicine and life
Dementia
upin humans3downin humans1+8% increased riskOR 1.6
3 studies
Dementia
upin humans3downin humans1+8% increased riskOR 1.6
HbA1c is linked with a lower risk of dementia in humans (HR 0.64; 95% CI, 0.51-0.79).
“among those with Poor baseline control (≥9.0%), trajectory improvement conferred substantial neuroprotection, reducing the risk of dementia (HR 0.64; 95% CI, 0.51-0.79) and mortality”
Humanstrajectory improvement in patients with Poor baseline control (≥9.0%) after SGLT2 inhibitor initiation
HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia
Journal of Alzheimer's disease : JAD
HbA1c is linked with a higher risk of dementia in humans (HR 1.39; 95% CI, 1.11-1.74).
“in patients with Fair baseline control (7.0-8.9%), worsening to Poor control significantly increased dementia (HR 1.39; 95% CI, 1.11-1.74) and mortality risks.”
Humansworsening to Poor control in patients with Fair baseline control (7.0-8.9%) after SGLT2 inhibitor initiation
HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia
Journal of Alzheimer's disease : JAD
HbA1c is associated with dementia in humans (older adults with diabetes without cognitive impairment or dementia at baseline) (OR 1.60, 95% CI 1.28–1.99).
“elevated HbA1c levels in elderly diabetic patients were significantly associated with dementia (OR = 1.60, 95% CI: 1.28–1.99)”
Reviewolder adults with diabetes without cognitive impairment or dementia at baselinen = 4,677
BMC geriatrics
HbA1c raises the risk of dementia in individuals with diabetes (8% increased risk).
“an 8% increased risk of dementia was associated with every 1% increase in HbA1c”
Reviewin individuals with diabetesevery 1% increase in HbA1c
Cureus
SGLT2 inhibitors
downin humans3−38% diabetic patients achieved better control
3 studies
SGLT2 inhibitors
downin humans3−38% diabetic patients achieved better control
SGLT2 inhibitors are associated with HbA1c in patients with T2DM.
“Regarding inflammatory markers, ferritin levels declined significantly (p = 0.001), along with HbA1c values (p < 0.001), ESR (p = 0.02), and CRP concentrations (p = 0.007).”
Human trialin patients with T2DM6 monthsn = 51
Research SquarePreprint
SGLT2 inhibitors are associated with HbA1c in humans (type 2 diabetes; uncontrolled comparison with baseline) (Decreased by 1.0% (95% CI 0.8–1.1)).
“HbA1c decreased by 1.0% (95% CI 0.8-1.1; n = 398)”
Humanstype 2 diabetes; uncontrolled comparison with baseline12 monthsn = 398
Journal of clinical medicine
SGLT2 inhibitors are associated with HbA1c in humans (type 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison).
“After six months, significant reductions were observed in body mass index, systolic blood pressure, heart rate, HbA1c,”
Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparisonempagliflozin 10 mg/day or dapagliflozin 10 mg/day6 monthsn = 51
Research SquarePreprint
SGLT2 inhibitors are associated with HbA1c in diabetic patients (38.2% of diabetic patients achieved better control).
“38.2% of diabetic patients achieved better HbA1c control”
Humansin diabetic patients
Frontiers in cardiovascular medicine
Frailty
upin humans3OR 2.4
3 studies
Frailty
upin humans3OR 2.4
Frailty is associated with HbA1c in humans (type 2 diabetes mellitus) (8.003±2.395 vs 6.774±1.741, p=0.036).
“The HBA1c level of patients with frailty was significantly higher compared to those without frailty (8.003±2.395 vs 6.774±1.741; p=0.036)”
Humanstype 2 diabetes mellitusn = 113
Philippine Journal of Internal Medicine
Frailty is associated with HbA1c in humans (type 1 diabetes) (p = 0.025).
“Frailty was associated with higher HbA1c (p = 0.025) and lower MoCA scores (p = < 0.001).”
Humanstype 1 diabetesn = 83
Diabetic medicine : a journal of the British Diabetic Association
HbA1c is associated with frailty in humans (HbA1c ≥ 9.0% in older adults with type 2 diabetes) (OR = 2.4, 95%CI 1.08–5.3).
“having HbA1c ≥ 9.0% (OR = 2.4, 95%CI 1.08–5.3)”
HumansHbA1c ≥ 9.0% in older adults with type 2 diabetesn = 840
Cognitive frailty and associated factors in older adults with type 2 diabetes in rural Vietnam
BMC geriatrics
Cardiovascular disease
upin humans3HR 1.21
3 studies
Cardiovascular disease
upin humans3HR 1.21
HbA1c is associated with cardiovascular disease in humans (unadjusted analyses).
“Higher HbA1c levels were associated with increased odds of cardiovascular outcomes in unadjusted analyses.”
Humansunadjusted analysesn = 30,804
Cureus
HbA1c is linked with a higher risk of cardiovascular disease in humans.
“HbA1c similarly enhanced risk of CVD.”
Humans
Cardiovascular Disease Risk Prediction in Type 1 Diabetes over 30 Years
ADA Scientific Sessions 2026 abstract
HbA1c is linked with a higher risk of cardiovascular disease in humans (type 1 diabetes) (HR 1.21, p<0.05).
“most important CVD factors for males were age, stroke/congestive heart failure history, mean (M) pulse, M insulin dose, TRG, and M HbA1c [hazard ratio (HR):1.09 p<0.0001; 3.84 p<0.01; 1.04 p<0.05; 3.27 p<0.05; 2.55 p<0.05; 1.21 p<0.05]”
Humanstype 1 diabetes~30 yearsmalesn = 761
Relative Importance of CVD Risk Factors in Type 1 Diabetes Males and Females
ADA Scientific Sessions 2026 abstract
Liraglutide discontinuation
upin humans1
1 study
Liraglutide discontinuation
upin humans1
liraglutide discontinuation is associated with HbA1c in humans (median +2.2% (range 0.8–3.5%)).
“After 12 weeks of liraglutide discontinuation, all patients experienced increases in HbA1c and body weight, with median changes of 2.2% (24 mmol/mol; range 0.8–3.5% [9–38 mmol/mol]; p=0.026) and 3.7% (range 3.2–4.8%; p=0.001), respectively.”
Human trial12 weeksn = 5
Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes
Frontiers in endocrinology
liraglutide discontinuation is associated with HbA1c in humans (congenital generalized lipodystrophy; after liraglutide discontinuation) (Median increase, 2.2%).
“Twelve weeks after liraglutide discontinuation, median HbA1c and body weight increased by 2.2% (p=0.026) and 3.7% (p=0.001), respectively.”
Human trialcongenital generalized lipodystrophy; after liraglutide discontinuation12 weeks after discontinuation
Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes
Frontiers in endocrinology
Hydroxytyrosol-glucuronide
downin humans1
1 study
Hydroxytyrosol-glucuronide
downin humans1
Hydroxytyrosol-glucuronide is associated with HbA1c in humans during the EVOO period (Spearman’s rho = −0.49).
“During the EVOO period, increases in urinary hydroxytyrosol-glucuronide were inversely correlated with decreases in HbA1c (Spearman’s rho = −0.49, p = 0.011) and with reductions in WHR (rho = −0.38, p = 0.048), whereas no significant associations were observed for waist circumference (rho = −0.20, p = 0.300) or WHtR (rho = −0.20, p = 0.310”
Human trialduring the EVOO period4 weeksn = 30
Antioxidants (Basel, Switzerland)
Hydroxytyrosol-glucuronide is associated with HbA1c in humans during EVOO intake (rho = -0.49, p = 0.011).
“urinary hydroxytyrosol-glucuronide during EVOO intake were inversely correlated with changes in HbA1c (Spearman's rho = -0.49, p = 0.011)”
Human trialduring EVOO intaken = 28
Antioxidants (Basel, Switzerland)
Catecholamines
downin humans1
1 study
Catecholamines
downin humans1
Catecholamines are associated with HbA1c in humans (changes following AM aerobic exercise training in adults with overweight or obesity) (r = −0.61, p = 0.01).
“This change in catecholamines was correlated with changes in HbA1C (r = −0.61, p = 0.01)”
Human trialchanges following AM aerobic exercise training in adults with overweight or obesity15 weeks
Metabolites
Disposition index
upin humans1
1 study
Disposition index
upin humans1
HbA1c is associated with disposition index in humans (Greater HbA1c reduction in multivariable models).
“In multivariable models, greater HbA1c reduction was associated with higher DI at Week 104.”
Human trialGreater HbA1c reduction in multivariable models104 weeks
Diabetes, obesity & metabolism
Nutrition counseling and exercise program
downin humans1
1 study
Nutrition counseling and exercise program
downin humans1
Nutrition counseling and exercise program is associated with HbA1c in humans (breast cancer survivors with BMI ≥ 25 kg/m2; single-arm study).
“At 3 months, significant reductions were observed in BMI, body fat composition, and hemoglobin A1c (HbA1c)”
Human trialbreast cancer survivors with BMI ≥ 25 kg/m2; single-arm study3 monthsn = 59
Cancers
All 228Fewer
Funding
6 grants since 2018National Institute of Diabetes and Digestive and Kidney Diseases$3.4MUK Research and Innovation£734KWellcome Trust£4.9M
Towards optimizing diabetes management and diagnosis by personalizing HbA1c targets
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Cincinnati$638K2020–2027
Towards a type 2 diabetes precision diagnosis approach with glycated haemoglobin (HbA1c) measurement
Wellcome TrustUniversity of Exeter£4.9M2024–2032
European Innovation CouncilVrije Universiteit Brussel€3M2022–2026
UK Research and InnovationUniversity of Leicester£364K2018–2023
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary rewritten as its findings changed.
As it read before
HbA1c has a U-shaped association with mortality in a general-population cohort, while a preprint links higher HbA1c with greater frailty and mortality in adults with diabetes. Human trials report reductions with semaglutide, tirzepatide and resistance training; a dapagliflozin trial shows no clear effect on HbA1c.
Summary rewritten as its findings changed.
As it read before
Higher HbA1c is associated with greater frailty in adults with diabetes in a preprint, while a general-population cohort reports a U-shaped association with mortality. A study in type 2 diabetes links HbA1c to cardiovascular disease or death and kidney-function decline; trials report reductions with semaglutide, tirzepatide and resistance training, while a dapagliflozin trial reports no between-group HbA1c difference.
Summary rewritten as its findings changed.
As it read before
Higher HbA1c is associated with frailty in adults with diabetes in a preprint, while a general-population cohort reports a U-shaped association with mortality. Another human study links HbA1c to multimorbidity; trials in type 2 diabetes report reductions with metformin, semaglutide and tirzepatide.
Summary rewritten as its findings changed.
As it read before
Human studies associate HbA1c with mortality and multimorbidity. Mortality associations are U-shaped in the general population; a preprint links higher HbA1c to greater frailty in adults with diabetes. Human trials report reductions with semaglutide, tirzepatide and metformin in type 2 diabetes.
Summary rewritten as its findings changed.
As it read before
Human trials report HbA1c reductions with semaglutide in type 2 diabetes and with exercise in prediabetes. Human studies link higher HbA1c to frailty, disability, mortality and diabetic complications. Cardiac biomarker results differ: a cross-sectional preprint reports an association with hsTnT, while a study in people with prediabetes finds none.